COVidIVERmectin: Ivermectin for Treatment of Covid-19
Status:
Terminated
Trial end date:
2021-06-08
Target enrollment:
Participant gender:
Summary
Prospective, multi-centre, randomized, double-blind trial to assess efficacy and safety of
ivermectin for the treatment of initial infection with SARS-CoV2 infection.
Study arms: A) placebo B) ivermectin 600 μg/kg daily for 5 consecutive days (I_600) +
placebo. C) ivermectin 1200 μg/kg daily at empty stomach with water for 5 consecutive days
(I_1200). Patients will be randomized at emergency room of hospitals as well as at outpatient
ambulatory care as well as at home, according to routine procedures of recruiting centres.
In arm A and B, the number of placebo tablets to be administered will be calculated by the
study dedicated pharmacist considering the number of tablets that should be taken in case a
patient with the same weight is assigned to arm C.